Search results: “Abl”

Here, we present data for the ready-to-use PathHunter® Checkpoint assays that target clinically relevant co-inhibitory and co-stimulatory checkpoint receptors and…

Checkpoint blockade antibodies are established cancer therapeutics. However, in recent years, agonistic antibodies have emerged as therapeutics not only for…

Discover valuable insights on breakthroughs, innovative strategies, and cell-based approaches for immunotherapeutic discovery and development.

Discover valuable insights on breakthroughs, innovative strategies, and cell-based approaches for immunotherapeutic discovery and development.

The MAS-related Gq protein-coupled receptor X4 (MRGPRX4) is poorly investigated. MRGPRX4 has been proposed to be involved in pain transmission,…

Systemic therapy of advanced hepatocellular carcinoma (HCC) with the small molecule multi-kinase inhibitor sorafenib is associated with large inter-individual pharmacokinetic…

Regulatory T cells (Tregs) are indispensable for maintaining self-tolerance by suppressing conventional T cells. On the other hand, Tregs promote…

Class I therapeutic antibodies achieve their clinical efficacy by binding to their target antigen and through Fragment crystallisable region (Fc)…

As newer, cutting-edge therapeutic technologies emerge, an increasing need for rapid and reliable screening tools follows.

A novel and growing modality in drug discovery has been the application of Targeted Protein Degradation (TPD). TPD involves the…

Eurofins DiscoverX, in conjunction with Drug Target Review, sponsored and moderated a Bioassay roundtable discussion webinar with group leaders from…